article thumbnail

And so pharma profiteers again

World of DTC Marketing

One of the biggest problems with a system that directs medical research towards profits rather than needs is that R&D funding is channelled to those products that can make pharma companies the most money. The best prospects are drugs targeted at patients who are high-value and who will use the drugs long term.

Pharma 147
article thumbnail

Optimising drug release of personalised 3D printed tablets

European Pharmaceutical Review

“The ability to predict dissolution curves based on tablet structure, and vice versa, holds promising prospects for tablet design and the application of 3D printing in pharmaceuticals”, the authors explained. This paper is published in Pharmaceutical Research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Traditional Pharma Model Isn’t Working – It’s Time to Evolve!

PharmaKinnex

But what happens when that in-person meeting is no longer a viable option for your prospect? Bearing the brunt of these COVID19 restrictions, pharmaceutical reps have had a hard time getting in the door to make sales, and their employers have noticed: Limited In-Person Access To HCPs.

Pharma 52
article thumbnail

Dawn of a new indication: how to study drugs for aging 

Pharmaceutical Technology

The UK also faces similar regulatory challenges as some public health officials and drug regulators are slow to collaborate with pharmaceutical researchers on aging-related work. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

FDA 145
article thumbnail

Primate models in pharma: What the future holds

Pharmaceutical Technology

Pharmaceutical research has long relied on non-human primate models for early-stage discoveries, but their use continues to cause controversy. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.

Pharma 98